ChemoCentryx

ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights

ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis

October 2020 issue of BMJ Case Reports features pediatric GPA case with severe, multirelapsing disease that failed conventional therapies. Avacopan reduced both glucocorticoid dose & immunosuppressive treatments without another flare and disease in sustained remission at 35 months. https://pubmed.ncbi.nlm.nih.gov/33122227/

ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020

ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

Presentation at 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) shows presence of complement activation markers and elevated complement gene expression, including C5aR, supporting the hypothesis that complement is activated in HS skin lesions and targeting C5aR could reduce inflammatory responses without affecting they key role of complement in pathogen clearance. https://ir.chemocentryx.com/events-and-presentations/events

ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights https://ir.chemocentryx.com//chemocentryx-reports-second-q

ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis https://ir.chemocentryx.com//chemocentryx-submits-new-drug

CCXI identifies novel orally administered immune checkpoint inhibitor CCX559 for next generation cancer treatment + study presented at AACR meeting shows CCXI's orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models

ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses

ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights

ChemoCentryx to Hold First Quarter 2020 Financial Results Conference Call on Monday, May 11, 2020

ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020

The ChemoCentryx team showing our stripes in honor of Rare Disease Day 2020. #ShowYourStripes

ChemoCentryx is proud to be a part of Rare Disease Day 2020 #RareDiseaseDay. Today we recognize all those individuals and families affected by a rare disease. #ShowYourStripes

ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26.

ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference Wednesday, January 15 at 1:30 p.m. PT